journal
MENU ▼
Read by QxMD icon Read
search

Journal of Thoracic Oncology

journal
https://www.readbyqxmd.com/read/29777823/updated-efficacy-analysis-including-secondary-population-results-for-oak-a-randomized-phase-iii-study-of-atezolizumab-vs-docetaxel-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer
#1
L Fehrenbacher, J von Pawel, K Park, A Rittmeyer, D R Gandara, S Ponce Aix, J-Y Han, S M Gadgeel, T Hida, D L Cortinovis, M Cobo, D M Kowalski, F De Marinis, M Gandhi, B Danner, C Matheny, M Kowanetz, P He, F Felizzi, H Patel, A Sandler, M Ballinger, F Barlesi
INTRODUCTION: The efficacy and safety of atezolizumab vs docetaxel as second- or third-line treatment in patients with advanced non-small cell lung cancer in the primary (n=850; ITT850) and secondary (n=1225; ITT1225) efficacy populations of the randomized phase III OAK study at an updated data cutoff were assessed. METHODS: Patients received atezolizumab 1200mg or docetaxel 75mg/m2 intravenously every 3 weeks until loss of clinical benefit or disease progression, respectively...
May 16, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29775809/transient-asymptomatic-pulmonary-opacities-during-osimertinib-treatment-and-its-clinical-implication
#2
Hansang Lee, Ho Yun Lee, Jong-Mu Sun, Se-Hoon Lee, Youjin Kim, Song Ee Park, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
INTRODUCTION: Osimertinib is an oral, potent, irreversible 3rd generation EGFR tyrosine kinase inhibitor (TKI) approved for the treatment of T790M positive non-small cell lung cancer (NSCLC) patients who failed 1st or 2nd generation EGFR TKIs. Interstitial lung disease (ILD) is a rare complication with osimertinib, occurring in 1-3%. Recently, relatively high incidence of transient asymptomatic pulmonary opacities (TAPOs) which are different from ILD has been described. However, its clinical implication has not been fully determined yet...
May 15, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29775808/phase-ii-study-of-maintenance-pembrolizumab-in-patients-with-extensive-stage-small-cell-lung-cancer-sclc
#3
Shirish M Gadgeel, Nathan A Pennell, Mary Jo Fidler, Balazs Halmos, Philip Bonomi, James Stevenson, Bryan Schneider, Ammar Sukari, Jaclyn Ventimiglia, Wei Chen, Cathy Galasso, Antoinette Wozniak, Julie Boerner, Gregory P Kalemkerian
PURPOSE: To assess the efficacy of maintenance pembrolizumab in extensive-stage small cell lung cancer (SCLC) patients, after treatment with platinum/etoposide. PATIENTS AND METHODS: Extensive-stage SCLC patients with a response or stable disease following induction chemotherapy were eligible. Pembrolizumab at a dose of 200 mg IV every 3 weeks was initiated within 8 weeks of the last cycle of chemotherapy. The primary endpoint of the study was progression-free survival (PFS) from study registration, with overall survival (OS) as a key secondary endpoint...
May 15, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29775807/fir-efficacy-safety-and-biomarker-analysis-of-a-phase-ii-open-label-study-of-atezolizumab-in-pd-l1-selected-patients-with-non-small-cell-lung-cancer
#4
David R Spigel, Jamie E Chaft, Scott Gettinger, Bo H Chao, Luc Dirix, Peter Schmid, Laura Q M Chow, Rodney J Hicks, Larry Leon, Jill Fredrickson, Marcin Kowanetz, Alan Sandler, Roel Funke, Naiyer A Rizvi
INTRODUCTION: The FIR phase II study (NCT01846416) evaluated the efficacy and safety of anti-programmed death-ligand 1 (PD-L1) atezolizumab in advanced non-small-cell lung cancer (NSCLC) selected by tumor cell (TC) or tumor-infiltrating immune cell (IC) PD-L1 expression. METHODS: Patients with PD-L1 TC2/3 (PD-L1 staining on ≥5% of TC) or IC2/3 tumors (PD-L1 staining on ≥5% of IC; determined by SP142 PD-L1 immunohistochemistry assay) with paired fresh and archival histology samples were recruited into Cohort 1 (chemotherapy-naïve/>6 months between adjuvant chemotherapy and recurrence), Cohort 2 (≥ second-line without brain metastases), or Cohort 3 (≥ second-line with treated brain metastases)...
May 15, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29775806/case-report-cd103-cd8-lymphocytes-characterize-the-immune-infiltration-in-a-case-with-pseudoprogression-in-sqnsclc
#5
Pedro Rocha, Max Hardy-Werbin, Dolores Naranjo, Álvaro Taus, Maite Rodrigo, Flavio Zuccarino, René Roth, Oliver Wood, Christian H Ottensmeier, Edurne Arriola
No abstract text is available yet for this article.
May 15, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29775805/new-subsolid-pulmonary-nodules-in-lung-cancer-screening-a-brief-report-of-the-nelson-trial
#6
Joan E Walter, Marjolein A Heuvelmans, Uraujh Yousaf-Khan, Monique D Dorrius, Erik Thunnissen, Anna Schermann, Harry J M Groen, Carlijn M van der Aalst, Kristiaan Nackaerts, Rozemarijn Vliegenthart, Harry J de Koning, Matthijs Oudkerk
INTRODUCTION: Low-dose computed tomography (LDCT) lung cancer screening is recommended in the United States. While new solid nodules after baseline screening have a high lung cancer probability at small size and require lower size cutoff values than baseline nodules, there only is limited evidence on management of new subsolid nodules. METHODS: Within the Dutch-Belgian randomized controlled LDCT lung cancer screening trial (NELSON), 7557 participants underwent baseline screening between April 2004 and December 2006...
May 15, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29763666/sarcoidosis-like-reactions-induced-by-checkpoint-inhibitors
#7
REVIEW
Ioannis Gkiozos, Alexandra Kopitopoulou, Alexandros Kalkanis, Vamvakaris N Ioannis, Marc A Judson, Kostas N Syrigos
No abstract text is available yet for this article.
May 12, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29753578/racial-ethnic-disparities-in-end-of-life-care-quality-among-lung-cancer-patients-a-seer-medicare-based-study
#8
Siddharth Karanth, Suja S Rajan, Gulshan Sharma, Jose-Miguel Yamal, Robert O Morgan
INTRODUCTION: Cancer end-of-life care and associated racial-ethnic disparities have been in focus during the last few years due to concerns regarding subjective care variations and poor quality of care. Given the high mortality rate and disease burden of lung cancer, end-of-life care quality is particularly crucial for this disease. This study uses previously validated measures and examines racial-ethnic disparities in lung cancer end-of-life care quality. METHODS: This study involves retrospective analysis of patients ≥66 years, who were diagnosed with stage I-IV lung cancer, and who died on or before December 31, 2013, using the Surveillance Epidemiology and End Result-Medicare data from 1991-2013...
May 10, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29753121/revised-modified-recist-criteria-for-assessment-of-response-in-malignant-pleural-mesothelioma-version-1-1
#9
Samuel G Armato, Anna K Nowak
Malignant pleural mesothelioma poses unique difficulties in tumor measurement and response assessment; however, robust and reproducible assessment of response is critically important in the conduct, interpretation, and reporting of clinical trials. The current de-facto standard for the assessment of mesothelioma tumor response, "modified RECIST" (Response Evaluation Criteria in Solid Tumors), was published in 2004 as a research paper. Practical application of the modified RECIST guidelines has suffered from varied interpretations, resulting in inaccuracies and inconsistencies in tumor response assessment across and within mesothelioma clinical trials...
May 9, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29753120/a-phase-i-trial-of-surgical-resection-and-intraoperative-hyperthermic-cisplatin-and-gemcitabine-for-pleural-mesothelioma
#10
Bryan M Burt, William G Richards, Hyun-Sung Lee, Sylvia Bartel, Marcelo C Dasilva, Ritu R Gill, Michael T Jaklitsch, Bruce E Johnson, Scott J Swanson, Raphael Bueno, David J Sugarbaker
INTRODUCTION: The primary objective of this single-institution Phase I clinical trial was to establish the maximum tolerated dose (MTD) of gemcitabine added to cisplatin delivered as heated intraoperative chemotherapy (HIOC) following resection of malignant pleural mesothelioma (MPM). METHODS: Extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D) treatment arms were based on investigators' assessment of patient fitness and potential for macroscopic complete resection...
May 9, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29751136/anti-epidermal-growth-factor-vaccine-antibodies-enhance-the-efficacy-of-tyrosine-kinase-inhibitors-and-delay-the-emergence-of-resistance-in-egfr-mutant-lung-cancer-cells
#11
Jordi Codony-Servat, Silvia García-Roman, Miguel Ángel Molina-Vila, Jordi Bertran-Alamillo, Ana Giménez-Capitán, Santiago Viteri, Andrés F Cardona, Erik d'Hondt, Niki Karachaliou, Rafael Rosell
INTRODUCTION: Mutations in EGFR correlate with impaired response to immune checkpoint inhibitors and the development of novel immunotherapeutic approaches for EGFR mutant non-small cell lung cancer (NSCLC) is of particular interest. Immunization against EGF has demonstrated efficacy in a phase III trial including unselected NSCLC patients, but little was known about the mechanisms involved in the effects of the anti-EGF antibodies generated by vaccination (anti-EGF VacAbs) or their activity in tumor cells with EGFR mutations...
May 8, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29751135/brief-report-on-the-detection-of-the-egfr-t790m-mutation-in-exhaled-breath-condensate-from-lung-cancer-patients
#12
Robert J Smyth, Sinead M Toomey, Alexander Sartori, Emer O Hanrahan, Sinead D Cuffe, Oscar S Breathnach, Ross K Morgan, Bryan T Hennessy
The EGFR-T790M somatic mutation is the most common mechanism of resistance to Tyrosine Kinase Inhibitors (TKI) in non-small cell lung cancer. Patients with advanced disease are not always amenable to repeat biopsy for further molecular analysis. Developing non-invasive methods to detect T790M in cell-free DNA (cfDNA), in the absence of tissue is being actively investigated. Unfortunately the low sensitivity of plasma for T790M detection has limited its clinical use. Exhaled breath condensate (EBC) is an easily collected sample, known to harbour cfDNA, including lung cancer mutations...
May 8, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29751134/sarcopenia-in-resected-non-small-cell-lung-cancer-effect-on-postoperative-outcomes
#13
Ryota Nakamura, Yoshihisa Inage, Rika Tobita, Satoshi Yoneyama, Takeshi Numata, Kyoko Ota, Hidetoshi Yanai, Takeo Endo, Yukinori Inadome, Shingo Sakashita, Hiroaki Satoh, Kenji Yuzawa, Toru Terashima
BACKGROUND: Skeletal muscle depletion, referred to as sarcopenia, has recently been identified as a risk factor for poor outcomes in various malignancies. However, the prognostic significance of sarcopenia in patients with non-small cell lung cancer (NSCLC) following surgery has not been adequately determined. This study investigated the impact of sarcopenia in patients undergoing pulmonary resection for lung cancer. METHODS: This retrospective study consisted of 328 patients with pathologically confirmed NSCLC who underwent curative resection between January 2005 and April 2017...
May 8, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29738824/radiologic-pseudoprogression-during-anti-pd1-therapy-for-advanced-non-small-cell-lung-cancer
#14
Sharyn I Katz, Mark Hammer, Stephen Bagley, Charu Aggarwal, Joshua Bauml, Jeffrey C Thompson, Arun C Nachiappan, Charles B Simone, Corey Langer
INTRODUCTION: Anti-PD1 (programmed cell death protein 1) therapy can lead to unconventional tumor responses including radiologic pseudoprogression. Here we determine the real-world incidence of radiologic pseudoprogression in advanced non-small cell lung cancer (NSCLC) and compare radiologic response criteria for disease response assessment. METHODS: Electronic medical records of all NSCLC patients receiving anti-PD1 therapy at our institution over a 3-year period were retrospectively reviewed and patients with clinically suspected radiologic pseudoprogression identified...
May 5, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29733909/radiosensitivity-of-lung-metastases-by-primary-histology-and-implications-for-stereotactic-body-radiation-therapy-using-the-genomically-adjusted-radiation-dose
#15
Kamran A Ahmed, Jacob G Scott, John A Arrington, Arash O Naghavi, G Daniel Grass, Bradford A Perez, Jimmy J Caudell, Anders E Berglund, Eric A Welsh, Steven A Eschrich, Thomas J Dilling, Javier F Torres-Roca
INTRODUCTION: We assessed the radiosensitivity of lung metastases based on primary histology using a validated gene signature and model lung metastases for the genomically adjusted radiation dose (GARD). METHODS: Tissue samples were identified from our prospective observational protocol. The radiosensitivity index (RSI) 10 gene assay was run on samples and calculated alongside GARD using the previously published algorithms. A cohort of 105 patients with 137 lung metastases treated with SBRT at our institution was used for clinical correlation...
May 4, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29733908/the-impact-of-staging-by-positron-emission-tomography-on-overall-survival-and-progression-free-survival-in-patients-with-locally-advanced-non-small-cell-lung-cancer
#16
Everett E Vokes, Ramaswamy Govindan, Neill Iscoe, Anwar M Hossain, Belen San Antonio, Nadia Chouaki, Marianna Koczywas, Suresh Senan
OBJECTIVE: We investigated the potential impact of stage migration because of positron emission tomography (PET) scan staging on survival in the locally advanced (Stage IIIA/B) non-small cell lung cancer (NSCLC) setting. METHODS: In PROCLAIM, 598 patients with stage IIIA/B nonsquamous NSCLC (intent-to-treat [ITT] population) were randomized to either pemetrexed plus cisplatin and concurrent thoracic radiotherapy (TRT) for 3 cycles followed by 4 cycles of pemetrexed consolidation or etoposide plus cisplatin and concurrent TRT for 2 cycles followed by a consolidation platinum-based doublet regimen for up to 2 cycles...
May 4, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29730379/italian-nivolumab-expanded-access-program-in-nonsquamous-non-small-cell-lung-cancer-patients-results-in-never-smokers-and-egfr-mutant-patients
#17
M C Garassino, A J Gelibter, F Grossi, R Chiari, H Soto Parra, S Cascinu, F Cognetti, D Turci, L Blasi, C Bengala, E Mini, E E Baldini, S Quadrini, G L Ceresoli, P Antonelli, E Vasile, C Pinto, G Fasola, D Galetta, M Macerelli, D Giannarelli, G Lo Russo, F de Marinis
BACKGROUND: Nivolumab is the first checkpoint inhibitor approved for the treatment of nonsquamous non-small-cell lung cancer (nonsq-NSCLC). We report results from the nivolumab Italian expanded access program (EAP), focusing on never-smokers and EGFR-mutant patients with nonsq-NSCLC. PATIENTS AND METHODS: Nivolumab (3 mg/kg intravenously every 2 weeks) was administered upon physicians' request for patients who had relapsed after ≥1 prior systemic treatment for stage IIIB/IV nonsq-NSCLC...
May 3, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29730378/vogt-koyanagi-harada-syndrome-induced-by-pembrolizumab-in-a-patient-with-non-small-cell-lung-cancer
#18
Tomoki Tamura, Etsuko Akimoto, Chiaki Matsumoto, Syunta Mori, Tatuya Nishi, Kennichiro Kudo, Syouichi Kuyama
No abstract text is available yet for this article.
May 3, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29723688/braf-mutant-lung-cancer-pd-l1-expression-tumor-mutational-burden-microsatellite-instability-status-and-response-to-immune-check-point-inhibitors
#19
Elizabeth Dudnik, Nir Peled, Hovav Nechushtan, Mira Wollner, Amir Onn, Abed Agbarya, Mor Moskovitz, Shoshana Keren, Noa Popovits-Hadari, Damien Urban, Moshe Mishaeli, Alona Zer, Aaron M Allen, Natalie Maimon Rabinovich, Ofer Rotem, Teodor Kuznetsov, Tzippy Shochat, Laila C Roisman, Jair Bar
INTRODUCTION: The efficacy of immune check-point inhibitors (ICPi) in BRAF mutant NSCLC is unknown. METHODS: Multi-institutional retrospective chart review identified 39 patients with BRAF mutant NSCLC. The patients were divided into two groups: V600E (Group A, n=21) and non-V600E (Group B, n=18). PD-L1 expression, tumor mutational burden (TMB) and microsatellite instability status (MSI) were assessed in 29 (74%), 11 (28%) and 12 (31%) patients, respectively. ORR, PFS with ICPi and OS were analyzed...
April 30, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29723687/new-insights-on-diagnostic-reproducibility-of-biphasic-mesotheliomas-a-multi-institutional-evaluation-by-the-international-mesothelioma-panel-from-the-mesopath-reference-center
#20
F Galateau Salle, N Le Stang, A G Nicholson, D Pissaloux, A Churg, S Klebe, V Roggli, H Tazelaar, J M Vignaud, R Attanoos, M B Beasley, H Begueret, F Capron, L Chirieac, M C Copin, S Dacic, C Danel, A Foulet-Roge, A Gibbs, S Giusiano-Courcambeck, K Hiroshima, V Hofman, A Husain, K Kerr, A Marchevsky, K Nabeshima, J M Picquenot, I Rouquette, C Sagan, J Sauter, F Thivolet, W D Travis, M S Tsao, B Weynand, F Damiola, A Scherpereel, J C Pairon, S Lantuejoul, V Rusch, N Girard
BACKGROUND: The 2015 WHO classified malignant mesothelioma into epithelioid [EM], biphasic [BM] and sarcomatoid [SM] for prognostic relevance and treatment decisions. The survival of BM is suspected to correlate with the amount of the sarcomatoid component. The criteria for a sarcomatoid component and the interobserver variability between pathologists for identifying this component are not well described. In ambiguous cases, a "transitional"[TM] subtype has been proposed but was not accepted as a specific subtype in the 2015 WHO...
April 30, 2018: Journal of Thoracic Oncology
journal
journal
41363
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"